Today’s Solutions: October 24, 2021

Cancer researchers celebrate the “fantastic” results of early trials for a new treatment that demonstrated its ability to significantly shrink tumors in half of the patients suffering from an advanced form of ovarian cancer.

The new treatment is comprised of a revolutionary drug combination that works together to obstruct the signals cancer cells need to grow. This could potentially offer an effective treatment option for individuals with a specific type of ovarian cancer that doesn’t normally respond to chemotherapy or hormone therapy.

The two drugs are known as VS-6766 and defactinib. The phase one trial of the novel treatment was led by a team at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS Foundation Trust and was administered to patients with low-grade serious ovarian cancer.

According to experts, this type of cancer often develops at a younger age. Less than 13 percent of patients respond to chemotherapy and less than 14 percent respond to hormone therapy.

Out of the 24 patients evaluated in the first trial, 46 percent saw a significant shrinkage in their tumors because of the treatment. For patients with a specific mutation, the results were even better. This indicates that the tumor profiles can help identify which patients are more likely to benefit from the new treatment.

Participants in the trial, who were between ages 31 and 75, lived for an average of 23 months before their cancer progressed.

“Overcoming cancer’s ability to evolve resistance to treatment is a huge challenge for cancer research,” explained Professor Kristian Helin, the chief executive of the ICR. “This study has turned a deep understanding of how cancer fuels its growth and develops resistance into a highly targeted treatment for patients who currently have few treatment options.”

Impressively, the novel drug combination worked in patients who already received a MEK inhibitorsomething that can cause tumors to shrink but often loses much of its effect as tumors develop resistance to treatment before the study.

ICR Dr. Susana Banerjee, consultant medical oncologist and research lead at the Royal Marsden’s gynecology unit, said: “I am delighted that this drug combination has worked so well in a group of patients who are in urgent need of new treatments, including those who have previously been treated with a MEK inhibitor. We’re very hopeful that this could become the standard of care for women with low-grade serious ovarian cancer.”

The results from the early trials were presented at the European Society for Medical Oncology congress. The first trials were so successful that they have already begun the phase two trials.

Solutions News Source Print this article
More of Today's Solutions

Algae wrapped in droplets improves efficiency of artificial photosynthesis

In our quest for the most sustainable, most renewable sources of energy, humanity continues to look to nature for inspiration. One of nature’s most efficient energy systems is photosynthesis, which is how plants convert sunlight, ... Read More

Evidence shows Vikings arrived in Americas nearly 500 years before Columbus

Researchers have known for a while that Vikings from Greenland founded the village of L’Anse aux Meadows in Newfoundland around the turn of the millennium, but now, a study published in Nature has finally pinpointed ... Read More

Egypt’s State Council swears-in the nation’s first female judges

Egypt’s State Council was established in 1946 and is an independent judicial body that deals with administrative disputes, disciplinary cases, appeals, reviews draft laws, decisions, and contracts that involve the government or a government-run body. ... Read More

Is group or individual work more productive? Here’s what science says

Are you a group project person or do you prefer to fly solo? We all have our work preferences, but what does science say about teamwork and productivity? A new study conducted by Quartz aims ... Read More

Wildlife filmaker provides a unique insight into the daily lives of bees

You may have seen bees flying around your backyard or local park, but it can be difficult for the naked human eye to grasp the full complexity of the lives of these pollinators. During the ... Read More